- Home
- ANIP
as 09-12-2025 11:30am EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 2.0B | IPO Year: | N/A |
| Target Price: | $86.00 | AVG Volume (30 days): | 488.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $99.50 | Next Earning Date: | 11-07-2025 |
| Revenue: | $747,399,000 | Revenue Growth: | 38.68% |
| Revenue Growth (this year): | 39.32% | Revenue Growth (next year): | 9.62% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pera Antonio R | ANIP | Director | Sep 3 '25 | Sell | $94.94 | 7,292 | $692,302.48 | 22,660 | |
| Leonard Matthew J | ANIP | N/A | Aug 25 '25 | Sell | $90.62 | 2,528 | $229,087.36 | 6,864 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Aug 22 '25 | Sell | $91.10 | 1,763 | $160,609.30 | 62,896 | |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Aug 21 '25 | Sell | $90.44 | 52,988 | $4,792,234.72 | 431,920 | |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Aug 20 '25 | Sell | $90.27 | 47,012 | $4,243,773.24 | 431,920 | |
| Pera Antonio R | ANIP | N/A | Aug 20 '25 | Sell | $89.73 | 5,421 | $486,426.33 | 22,660 | |
| Thoma Jeanne | ANIP | N/A | Aug 18 '25 | Sell | $89.32 | 21,540 | $1,920,369.65 | 23,405 | |
| Leonard Matthew J | ANIP | N/A | Aug 18 '25 | Sell | $88.17 | 6,937 | $611,635.29 | 6,864 | |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Aug 15 '25 | Sell | $87.15 | 52,990 | $4,618,078.50 | 431,920 | |
| Gassert Chad | ANIP | SVP - CORP. DEV. & STRATEGY | Aug 15 '25 | Sell | $86.97 | 20,000 | $1,739,400.00 | 173,226 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
Zacks
4 days ago
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Zacks
4 days ago
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
StockStory
2 months ago
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q1 Earnings Call
Argus Research
3 months ago
ANIP: Raising target price to $70.00
StockStory
3 months ago
ANI Pharmaceuticals (NASDAQ:ANIP) Q1 Earnings: Leading The Generic Pharmaceuticals Pack
StockStory
3 months ago
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
GlobeNewswire
3 months ago
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.